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Abstract. The missense P39L variant in the prion protein gene (PRNP) has recently been associated with frontotemporal
dementia (FTD). Here, we analyzed the presence of the P39L variant in 761 patients with FTD and 719 controls and found a
single carrier among patients. The patient was a 67-year-old male, with a positive family history for dementia, who developed
apathy, short term memory deficit, and postural instability at 66. Clinical and instrumental workup excluded prion disease. At
MRI, bilateral frontal lobe atrophy was present. A diagnosis of FTD was made, with a mainly apathetic phenotype. The PRNP
P39L mutation may be an extremely rare cause of FTD (0.13%).
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INTRODUCTION
Over the past years, several genes have been
identified as causative of autosomal dominant fron-
totemporal dementia (FTD), including microtubule
associated protein tau gene (MAPT), progranulin
(GRN), and C9ORF72 (see [1] for review).
In addition, prion protein gene (PRNP) mutations
have been associated with clinical pictures mim-
icking neurodegenerative diseases [2, 3]. So far,
different mutations associated with clinical phenotype
mimicking FTD with behavioral disturbances and/or
parkinsonism have been found, mainly in C-terminal
region [4, 5]. Moreover, a novel missense P39L muta-
tion in PRNP has been recently reported in two patients
with FTD syndrome [6] who were negative for muta-
tions in genes causative of dementia known to date.
Here, we analyzed 761 Italian patients with FTD
and 719 controls for the presence of the PRNP P39L
mutation and found a carrier in patients and none in
controls.
POPULATION AND METHODS
Subjects
Seven hundreds sixty one patients (374 males and
387 females; mean age ± standard deviation (SD):
67.2 ± 8.8 years; mean age ± SD at onset: 62.8 ± 4.3
years) with FTD were recruited at: Alzheimer Unit
of the Fondazione Ca´ Granda, IRCCS Ospedale Mag-
giore Policlinico, University of Milan (Milan), Center
for Research and Treatment of Cognitive Dysfunc-
tions, “Luigi Sacco” Hospital (Milan), University of
Torino (Torino), University of Florence (Florence),
University Sapienza (Rome), IRCCS Istituto Centro
San Giovanni di Dio- Fatebenefratelli (Brescia).
All patients underwent a standard battery of exam-
inations, including medical history, physical and
neurological examination, screening laboratory tests,
neurocognitive evaluation, and imaging. Cognitive
dysfunctions were assessed by the Clinical Demen-
tia Rating (CDR), the Mini-Mental State Examination
(MMSE), the Frontal Assessment Battery (FAB), the
Wisconsin Card Sorting Test (WCST), and the Tower
of London test. The presence of significant vascu-
lar brain damage was excluded (Hachinski Ischemic
Score <4). The diagnosis of FTD was made accord-
ing to current consensus criteria [7] and subsequent
revisions [8, 9]. The control group consisted of 719
non-demented volunteers (343 male and 376 female
patients, mean age ± SD: 67.8 ± 9.3 years), matched
for ethnic background and age, without memory
and psycho-behavioral dysfunctions (MMSE ≥28).
Informed consent to participate in this study was given
by all subjects or their caregivers.
DNA isolation and genotyping
High-molecular weight DNA was isolated from
whole blood using a Flexigene Kit (Qiagen, Hildren,
Gemany), as described by the manufacturer. The
amount of DNA for each sample was determined by
measuring the optical density at 260 nm wavelengths
using a spectrophotometer (Eppendorf AG, Germany).
DNA samples were aliquoted and stored at –20◦C
until use.
This population was previously screened for GRN,
C9ORF72 and MAPT genes: 23 patients were carriers
of mutations in GRN, one of a mutation in MAPT and
56 of the expansion in the C9ORF72 [10].
Patients and controls were tested for PRNP P39L
mutation by allelic discrimination, using the Taq-
Man methodology. A specific custom probe for
this mutation has been designed (c116c t F; For-
ward Primer Seq: AGCCTGGAGGATGGAACACT;
c116c t R; Reverse Primer Seq: GGTAGCGGTTGC-
CTCCA) and labeled with 6-FAM and VIC as reporter
dyes and MGB-NFQ (ABI) as quencher. Assays were
performed in 20l reactions in 96 well plates using
a StepOne Plus instrument (ABI). PCR mix consisted
of 7.7l universal Master Mix, 1l probe and water
to reach the final volume. Thermocycling consisted of
10 min at 95◦C for AmpliTaqGold activation, and 50
cycles of 92◦C for 15 s and 60◦C for 1 min.
The presence of the variant was confirmed by
bidirectional sequencing analysis on an AB3130 auto-
mated sequencer (Applied Biosystems).
RESULTS
The PRNP P39L variant was identified in one out of
761 FTD cases and in none of 719 controls. The carrier
had the M129M genotype. The clinical and neuropsy-
chological features of patient-carrier are reported in
Table 1.
The patient was a 67-year-old male, who worked as
a bricklayer until the age of 58, when he retired. His
education was discontinued at primary school. Family
history was positive for dementia: his mother died at
the age of 70 with a 3-year history of dementia. In his
past medical history, he suffered from hypertension,
type II diabetes, dyslipidemia, chronic bronchitis, and
chronic renal failure. He had a history of alcohol abuse
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Table 1
Characteristics of the carrier
Gender Male
Age 67
Age at onset 66
Family History for dementia positive (mother)
Clinical features apathy
short term memory deficit
postural instability
emotional bluntness
anhedonia
episodes of aggressiveness
disorientation in space and partially in time
reduction of spontaneous speech
Neuropsychological characteristics Cognitive impairment: MMSE 17/30; FAB 5/18
CSF
14.3.3 absent
A 714 pg/ml
Tau 152 pg/ml
P-Tau 28 pg/ml
(two bottles of wine per day for 20 years from the age
of 40 to 60) and was a former smoker (20 cigarettes
per day for 40 years).
From the age of 66, he developed apathy, short-
term memory deficit, and postural instability with three
falls in one month. The symptoms rapidly progressed
and the patient was admitted to a hospital within one
month from their onset. During his stay, he under-
went neuropsychology testing (MMSE 17/30, FAB
5/18), multiple electroencephalogram (EEG), which
disclosed absence of periodism, electromyography,
which was consistent with mild chronic sensorimo-
tor axonal polyneuropathy, and MRI, that showed
bilateral frontal lobe atrophy, confluent lesions in the
white matter and no alteration in diffusion–weighted
imaging (DWI). He also underwent lumbar puncture
that showed a weak positivity for 14.3.3. Cere-
brospinal fluid (CSF) amyloid- (A) levels were
1031 pg/ml and total tau levels were 540 pg/ml (ref-
erence values: A ≥550 pg/ml; total tau: ≤375 pg/ml
[11]). Autoantibodies (paraneoplastic-anti Thyroglob-
ulin and anti-Thyroperoxidase) were all negative
both in plasma and CSF. He came to our atten-
tion 6 months after symptom onset. The family
reported emotional bluntness, apathy, anhedonia, and
episodes of aggressiveness, but the clinical status had
remained stable. He was dependent on his family for
instrumental daily activity and required assistance in
self-care.
At clinical examination, the patient was disoriented
in space and partially in time (could just say the month
and the year). Spontaneous speech was reduced, but
he could answer questions when stimulated. Nam-
ing, comprehension and repetition were spared. The
speech was monotone, with reduced vocabulary. He
had difficulty sustaining attention and an apathetic
attitude.
His cranial nerves were intact, in particular his pur-
suit and saccades were normal. He did not have any
motor or sensory deficit. Deep tendon reflexes were
reduced symmetrically. Tone was mildly increased,
especially in lower limbs.
He was instable with mild multidirectional oscil-
lations. His gait was slow and cautious and could
make just few steps. He did not show any dysmetria.
Jaw jerk, glabellar, and palmo-mental reflexes were
present. Myoclonus was absent.
Brain MRI showed neither cortical ribboning nor
basal ganglia hyperintesities on DWI. Multiple lesions
in the white matter, interpreted as vascular lesions,
were observed, together with bilateral frontal lobe
atrophy. FDG-PET showed hypomethabolism in pre-
frontal cortex and insula bilaterally and in the right
caudate (Fig. 1). At EEG, no periodic complexes were
present.
The lumbar puncture was repeated. The 14.3.3 pro-
tein was absent, A levels were 714 pg/ml, total
tau levels were 152 pg/ml, phosphorylated-tau lev-
els were 28 pg/ml (reference value: ≤52 pg/ml [11]).
No oligoclonal bands were present. In addition, auto-
antibodies (Hu-Yo-Ri-Ma1-Ma2-CV2- amphiphysin)
were absent. Genetic testing was negative for MAPT,
GRN, and C9ORF72.
At 6-month follow up (one year from the onset), the
patient was still apathetic, anhedonic, dependent on
daily activity, and with double incontinence. He still
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Fig. 1. MRI: A) Coronal T1 showing frontal lobe atrophy bilaterally; B) Axial flair with the evidence of multiple confluent lesions in the white
matter; C) Axial diffusion–weighted imaging revealing neither hyperintensity in the cortex nor in the basal ganglia. D) FDG-PET showing
hypometabolism in prefrontal cortex, insula and right caudate.
needed help for walking and developed preference for
sweet food.
DISCUSSION
In this study, we screened 761 FTD patients and
719 controls in order to test whether the PRNP P39L
mutation may be causative of the disease. We found one
carrier, who presented this variation in heterozygosis
status, whereas in controls it was absent.
These results suggest that the PRNP P39L muta-
tion is a very rare cause of FTD (frequency: 0.13%
in our population). Moreover, the patient ancestors
originated from Southern Italy, therefore it may be pos-
sible that he has a common founder with the patients
previously reported by Bernardi et al. [6]. Unfortu-
nately, we could not analyze the haplotype sharing in
these families to prove this hypothesis. Similarly to
such patients, this case presented with frontal demen-
tia dominated by dysexecutive syndrome whereas,
conversely, he did not show severe behavioral distur-
bances, but apathy/anhedonia instead. Neuroimaging
showed that atrophy was mainly frontal bilateral and
did not show temporal or left parietal atrophy like the
two previously described cases. This observation is
consistent with the absence of language problems in
this patient.
The presence of multiple lesions in the white mat-
ter, possibly due to vascular problems, considering his
history of hypertension, type II diabetes, dyslipidemia,
smoking and alcohol abuse, may be an additional fac-
tor in worsening the cognitive status of the patient. The
CSF analysis, together with the clinical and instrumen-
tal workup, excluded the diagnosis of Creutzfeld-Jakob
disease [12].
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Regarding the mechanism by which the variant is
involved in FTD pathogenesis, it still remains not
explained. It is, however, known that the N-terminal
domain of PrP is highly conserved across species,
suggesting it exerts a crucial biological role. It mod-
ulates “cellular Prp” conformer, which gives it a
neuroprotective function controlled by several ligands
[13]. The aminoacidic substitution could therefore pro-
duce a less rigid N-terminus with deleterious effects
[6].
In conclusion, the PRNP P39L mutation may be an
extremely rare cause of FTD, but the neuropathological
confirmation will be needed to validate this hypothe-
sis, preferably together with further replication in other
cohorts.
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